The Changing Face of Percutaneous Image-guided Biopsy: Molecular Profiling and Genomic Analysis in Current Practice.

Departments of Radiology (D.M., J.M.L., R.K.K.).
Journal of vascular and interventional radiology: JVIR (Impact Factor: 1.81). 06/2013; DOI: 10.1016/j.jvir.2013.04.027
Source: PubMed

ABSTRACT Oncology is undergoing a revolutionary change. Image-guided biopsy is expected to play an increasingly important role in this radical transformation. Current concepts of disease and treatment are based on an established set of physical signs and symptoms and laboratory tests broken down by organ system. However, soon diseases will be categorized and treated based on much more specific and detailed molecular and genetic information. This transformation in how disease is categorized and treated will depend on the ability to harvest tissue from tumors and analyze it appropriately.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Cancer is a leading cause of death worldwide. Great efforts are dedicated to the development of prognostic and predictive biomarkers to improve diagnosis and achieve optimal treatment selection, thereby, introducing precision medicine in the multimodality treatment of cancer. Genomic aberrations are the basis of tumour development, representing excellent candidates for the development of promising clinical biomarkers. Over the past decade, single-gene mutations and genomic profiling have been increasingly used in multidisciplinary consultations for risk-assessment and treatment planning for patients with cancer. We discuss the impact of such genetic-based information on surgical decision-making. Single-gene mutations have already influenced surgical decision-making in breast, colorectal and thyroid cancer. However, the direct impact of genomic profiling on surgical care has not yet been fully established. We discuss the direct and indirect influences of genomic profiling on surgery, and analyse the limitations and unresolved issues of a genotypic-approach to the surgical management of cancer.
    Nature Reviews Clinical Oncology 06/2014; 11(10). DOI:10.1038/nrclinonc.2014.101 · 15.03 Impact Factor
  • International Journal of Gynecological Cancer 01/2014; 24(1):2-3. DOI:10.1097/IGC.0000000000000060 · 1.94 Impact Factor